Log in

NASDAQ:STAASTAAR Surgical Stock Price, Forecast & News

-0.48 (-1.22 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $38.80
50-Day Range
MA: $37.40
52-Week Range
Now: $38.80
Volume261,864 shs
Average Volume362,474 shs
Market Capitalization$1.75 billion
P/E Ratio143.71
Dividend YieldN/A
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers intraocular lenses (IOLs), including collamer material and silicone foldable IOLs, and nanoFLEX IOL that produces a clearer image, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in China, Korea, India, and internationally. STAAR Surgical Company was founded in 1982 and is based in Monrovia, California.
Read More
STAAR Surgical logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.17 out of 5 stars

Industry, Sector and Symbol

Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:STAA



Sales & Book Value

Annual Sales$150.18 million
Cash Flow$0.56 per share
Book Value$3.66 per share


Net Income$14.05 million


Market Cap$1.75 billion
Next Earnings Date7/29/2020 (Estimated)

Receive STAA News and Ratings via Email

Sign-up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.

STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions

How has STAAR Surgical's stock been impacted by COVID-19 (Coronavirus)?

STAAR Surgical's stock was trading at $28.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STAA stock has increased by 38.5% and is now trading at $38.80. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of STAAR Surgical?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for STAAR Surgical.

When is STAAR Surgical's next earnings date?

STAAR Surgical is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for STAAR Surgical.

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) announced its quarterly earnings results on Wednesday, May, 6th. The medical instruments supplier reported $0.04 EPS for the quarter, topping the Zacks' consensus estimate of $0.03 by $0.01. The medical instruments supplier earned $35.19 million during the quarter, compared to analyst estimates of $34.90 million. STAAR Surgical had a net margin of 8.21% and a return on equity of 12.52%. The business's quarterly revenue was up 8.0% on a year-over-year basis. View STAAR Surgical's earnings history.

What guidance has STAAR Surgical issued on next quarter's earnings?

STAAR Surgical updated its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $34.9-34.9 million, compared to the consensus revenue estimate of $32.22 million.

What price target have analysts set for STAA?

3 brokers have issued 1-year target prices for STAAR Surgical's shares. Their forecasts range from $37.00 to $44.00. On average, they expect STAAR Surgical's share price to reach $40.67 in the next twelve months. This suggests a possible upside of 4.8% from the stock's current price. View analysts' price targets for STAAR Surgical.

Has STAAR Surgical been receiving favorable news coverage?

News headlines about STAA stock have trended somewhat negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. STAAR Surgical earned a news sentiment score of -1.1 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutSTAAR Surgical.

Are investors shorting STAAR Surgical?

STAAR Surgical saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,910,000 shares, an increase of 5.8% from the April 15th total of 2,750,000 shares. Based on an average trading volume of 514,200 shares, the days-to-cover ratio is currently 5.7 days. Approximately 6.6% of the shares of the company are short sold. View STAAR Surgical's Current Options Chain.

Who are some of STAAR Surgical's key competitors?

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Ring Energy (REI), Ring Energy (REI), Rockwell Medical (RMTI), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Advanced Micro Devices (AMD) and Amarin (AMRN).

Who are STAAR Surgical's key executives?

STAAR Surgical's management team includes the following people:
  • Ms. Caren L. Mason, CEO, Pres & Director (Age 65)
  • Ms. Deborah J. Andrews, Chief Financial Officer (Age 62)
  • Dr. Keith Holliday, Chief Technology Officer (Age 56)
  • Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 57)
  • Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations, Direct Markets- Europe & China (Age 54)

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.46%), Baillie Gifford & Co. (4.38%), Capital International Investors (4.25%), State Street Corp (2.42%), Waddell & Reed Financial Inc. (2.31%) and TimesSquare Capital Management LLC (1.85%). Company insiders that own STAAR Surgical stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Graydon C Hansen, Jon K Hayashida, Keith Holliday, Samuel J Gesten, Scott D Barnes and William P Wall. View institutional ownership trends for STAAR Surgical.

Which institutional investors are selling STAAR Surgical stock?

STAA stock was sold by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., Principal Financial Group Inc., Kornitzer Capital Management Inc. KS, Driehaus Capital Management LLC, Two Sigma Advisers LP, Cadence Capital Management LLC, Nuveen Asset Management LLC, and BlackRock Inc.. Company insiders that have sold STAAR Surgical company stock in the last year include Deborah J Andrews, Graydon C Hansen, Jon K Hayashida, Keith Holliday, Samuel J Gesten, and Scott D Barnes. View insider buying and selling activity for STAAR Surgical.

Which institutional investors are buying STAAR Surgical stock?

STAA stock was bought by a variety of institutional investors in the last quarter, including TCW Group Inc., Ziegler Capital Management LLC, Rock Springs Capital Management LP, KAMES CAPITAL plc, Aviva PLC, Loomis Sayles & Co. L P, Capital International Investors, and First Trust Advisors LP. View insider buying and selling activity for STAAR Surgical.

How do I buy shares of STAAR Surgical?

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $38.80.

How big of a company is STAAR Surgical?

STAAR Surgical has a market capitalization of $1.75 billion and generates $150.18 million in revenue each year. The medical instruments supplier earns $14.05 million in net income (profit) each year or $0.46 on an earnings per share basis. STAAR Surgical employs 475 workers across the globe.

What is STAAR Surgical's official website?

The official website for STAAR Surgical is www.staar.com.

How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.